SRC Environmental Analytical Laboratories uses the latest rapid microbiological technology in cannabis microbial testing. Our methods are fully validated following United States Pharmacopeia (USP) guidance for alternative microbiological methods. These methods have improved specificity and sensitivity, as well as shortened incubation time.
- Fast turnaround time (as short as three business days for our rush option)
- Meets Health Canada regulatory requirements
- Competitive pricing
How do I pick the package that’s right for me?
Our microbial testing packages are created to test against the most common USP and European Pharmacopoeia (EP) specifications. Health Canada requires licence holders to select the specification appropriate for the intended or reasonably foreseeable use of the cannabis product they are producing. Refer to the tables below for commonly requested USP and EP microbial specifications.
Download Packages for Testing Microbial Contaminants in Cannabis
To request packages not listed here, please contact analytical@src.sk.ca.
1Standard USP Microbial PackagE
USP-NF <2023> | DRIED CANNABIS | CANNABIS EXTRACT |
---|---|---|
Total Aerobic Count | <100,000 cfu/g | <10,000 cfu/mL |
Total Yeast and Mold | <1,000 cfu/g | <1,000 cfu/mL |
BTGN Bacteria | <1,000 cfu/g | N/A |
Salmonella spp. | Absence in 10 g | Absence in 10 mL |
E. coli | Absence in 10 g | Absence in 10 mL |
2Standard EP microbial package
EP 5.1.8. C | |
---|---|
Total Aerobic Count | <100,000 cfu/g or mL |
Total Yeast and Mold | <10,000 cfu/g or mL |
BTGN Bacteria | <10,000 cfu/g or mL |
Salmonella spp. | Absence in 25 g or mL |
E. coli | Absence in 1 g or mL |
1,3USP/EP Finished Products Packages
USP/EP FINISHED PRODUCTS | |
---|---|
Total Aerobic Count | <100 cfu/g or mL |
Total Yeast and Mold | <10 cfu/g or mL |
BTGN Bacteria | Absence in 1 g or mL |
Salmonella spp. | Absence in 1 g or mL |
P. aeruginosa | Absence in 1 g or mL |
S. aureus | Absence in 1 g or mL |
1 Minimum 15 g or 15 mL of sample required.
2 Minimum 30 g or 30 mL of sample required.
3 Finished products include aqueous/nonaqueous preparation for oral use, inhalation, orodispersible films, and other routes of administrations. Refer to USP-NF <1111> or EP 5.1.4. for the complete list.